RBC Capital maintained an Outperform rating on Spectrum Pharmaceuticals (NASDAQ: SPPI) and lowered its price target to $12.00 (from $15.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE